Related Experiment Videos
The HTLV-I envelope glycoproteins: structure and functions
L Delamarre1, A R Rosenberg, C Pique
1CNRS URA 1156, Institut Gustave Roussy, Villejuif, France.
Summary
The human T-cell lymphotropic virus type I (HTLV-I) envelope glycoproteins have a compact structure essential for function. Most mutations cause loss of function due to abnormal maturation, indicating the entire structure is critical for HTLV-I infectivity.
Area of Science:
- Virology
- Structural Biology
- Molecular Biology
Background:
- The human T-cell lymphotropic virus type I (HTLV-I) envelope glycoproteins, SU and TM, are crucial for viral entry but their tertiary structure is poorly understood.
- These glycoproteins mature through the cellular secretory pathway, with N-glycosylation occurring at five potential sites.
Purpose of the Study:
- To investigate the structural organization and functional domains of HTLV-I envelope glycoproteins.
- To elucidate the role of protein conformation and maturation in HTLV-I infectivity.
Main Methods:
- Analysis of naturally occurring and artificially introduced mutations in HTLV-I glycoproteins.
- Studies utilizing neutralizing antibodies and mutagenesis to define functional domains.
- Sequence analysis of the HTLV-I TM protein.
Main Results:
- Most mutations lead to loss of function, primarily due to aberrant intracellular maturation, suggesting a compact and conformationally sensitive protein structure.
- Functional domains responsible for receptor binding are distributed throughout the SU glycoprotein.
- Sequence analysis predicts TM protein functions similar to other retroviral TMs, including roles in oligomerization and fusion.
Conclusions:
- The HTLV-I envelope glycoproteins possess a compact structure where the entire protein contributes to correct conformation and function.
- Abnormal intracellular maturation is a key factor in the loss of function observed with glycoprotein mutations.
- Further research is needed to confirm the predicted roles of the TM protein in viral fusion and to understand the non-infectious nature of free HTLV-I particles.